Victor Tse

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

26h-index3.8kcitations94works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(19), Glioma Diagnosis and Treatment(16), Advanced Breast Cancer Therapies(13), Angiogenesis and VEGF in Cancer(12), Immunotherapy and Immune Responses(12)

Publications93 total

Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression
Nucleic Acids Research·2025· 2 citedOpen Access
OpenASO: RNA Rescue—designing splice-modulating antisense oligonucleotides through community science
RNA·2025
Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin and silence gene expression
2025Open Access
Small molecule inhibition of CPSF3 impacts R-loop distribution and abundance
2025Open Access
A novel splice site variant in <i>DEGS1</i> leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolved
2025· 1 citedOpen Access
CyberKnife Treatment of Medically Intractable Trigeminal Neuralgia: A Comparison of Isocentric and Non-isocentric Treatment Planning Outcomes
Cureus·2025· 1 citedOpen Access
Supplementary Table S2 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S5 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S9 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S6 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S3 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S3 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S1 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S2 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S6 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S8 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S9 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Data from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Fig. S7 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
Supplementary Table S4 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
2025Open Access
page 1 of 5Next →

Frequent Co-authors

Lewis Hou(12), Justin Santarelli(9), Samuel Cheshier(8), Anand Veeravagu(7), Yun C. Yung(7), Irving L. Weissman(6), Gerald D. Silverberg(6), Hannes Vogel(5), Xiaohong Chen(5), Michael Hsiao(5), Andrew Hsu(4), Weibo Cai(4), M. Yashar S. Kalani(4), V.M. Udani(4), Amy J. Wagers(4), Linda M. Liau(3), Keyoumars Ashkan(3), David D. Tran(3), Jian Campian(3), John Trusheim(3)